These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38434941)

  • 1. The effect of rosuvastatin alone or in combination with fenofibrate or omega-3 fatty acids on lipoprotein(a) levels in patients with mixed hyperlipidemia.
    Agouridis AP; Filippatos TD; Kostapanos M; Kostara C; Tsimihodimos V
    Arch Med Sci Atheroscler Dis; 2024; 9():e26-e32. PubMed ID: 38434941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
    Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD
    Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.
    Agouridis AP; Kostapanos MS; Tsimihodimos V; Kostara C; Mikhailidis DP; Bairaktari ET; Tselepis AD; Elisaf MS
    Int J Clin Pract; 2012 Sep; 66(9):843-53. PubMed ID: 22897461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia.
    Agouridis AP; Tsimihodimos V; Filippatos TD; Tselepis AD; Elisaf MS
    Lipids; 2011 Jun; 46(6):521-8. PubMed ID: 21327725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels.
    Makariou SE; Liberopoulos EN; Agouridis AP; Challa A; Elisaf M
    J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):382-6. PubMed ID: 22431864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.
    Capuzzi DM; Morgan JM; Weiss RJ; Chitra RR; Hutchinson HG; Cressman MD
    Am J Cardiol; 2003 Jun; 91(11):1304-10. PubMed ID: 12767421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
    Kei A; Liberopoulos E; Tellis K; Rizzo M; Elisaf M; Tselepis A
    Eur J Clin Invest; 2013 Jul; 43(7):698-707. PubMed ID: 23600368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
    J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Rosuvastatin Versus Atorvastatin, Alone or in Combination, on Lipoprotein (a).
    Vavlukis M; Mladenovska K; Daka A; Dimovski A; Domazetovska S; Kuzmanovska S; Kedev S
    Ann Pharmacother; 2016 Aug; 50(8):609-15. PubMed ID: 27242350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
    Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
    Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
    Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial.
    Ihm SH; Chung WB; Lee JM; Hwang BH; Yoo KD; Her SH; Song WH; Chae IH; Park TH; Kim JH; Jeon DW; Cho BR; Kang SH; Park SD; Lee JB; Woo JT; Lee BW; Han KA; Won KH; Kim HS; Yu JM; Chung CH; Kim HJ; Cho HC; Seung KB
    Clin Ther; 2020 Oct; 42(10):2021-2035.e3. PubMed ID: 32891418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Efficacy and Safety of Fixed Dose Combination of Rosuvastatin and Choline Fenofibrate to Fixed Dose Combination of Rosuvastatin and Fenofibrate in Patients of Mixed Dyslipidemia: A Randomized, Open-label, Multicentre Clinical Trial in Indian Population.
    Barkate H; Patel P; Shah D; Vyas F
    Indian J Endocrinol Metab; 2018; 22(5):627-631. PubMed ID: 30294571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation].
    Polenova NV; Vaulin NA; Masenko VP; Iavelov IS; Gratsianskiĭ NA
    Kardiologiia; 2009; 49(2):9-14. PubMed ID: 19254210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles.
    Wang TD; Chen WJ; Lin JW; Cheng CC; Chen MF; Lee YT
    Atherosclerosis; 2003 Oct; 170(2):315-23. PubMed ID: 14612213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia.
    McKenney J; Jones M; Abby S
    Curr Med Res Opin; 2005 Sep; 21(9):1403-12. PubMed ID: 16197659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.